Stock Ticker

  • Loading stock data...

Merck (NYSE:MERK) Quits RSV Vaccine Development With Moderna (NASDAQ:MRNA), But Will Continue Oncology Collaboration

Merck & Co Inc. (NYSE:MERK) is returning all rights to the respiratory syncytial virus (RSV) vaccine to Moderna Inc. (NASDAQ:MRNA) barely after helping take the vaccine into the clinic. The vaccine dubbed mRNA-1172 used Merck‚Äôs lipid nanoparticle delivery. Merck to hand over RSV rights to Moderna The pharmaceutical company is doubling down on its in-house […]

Sign Up To Get Our Latest Stocks Alerts